The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / Articles / July / Moving Beyond Document-Based Validation
Bioprocessing Interviews Regulation & Standards Standards & Regulation Quality & Compliance Technology & Manufacturing Sponsored

Moving Beyond Document-Based Validation

How UCB is improving traceability, audit readiness, and visibility.

07/02/2026 1 min read Video

Share

Slow workflows, fragmented tools, and repeated data entry can make global validation harder to manage and inspections more difficult to prepare for. How can companies create a faster, more traceable process without simply digitizing existing inefficiencies?

Nadia Williams, Head of IT Compliance Solutions at UCB, explains how the company is moving toward a centralized, record-based validation platform. She also discusses UCB’s pilot-led approach to change, ensuring standardization and audit readiness, and the future potential of automation and AI.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: John Maher
Cell & Gene Power List Development & Clinical
Musings from The Power List: John Maher

August 14, 2026

4 min read

John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors

Why Cell Therapy Needs a Digital Backboned
Cell & Gene Development & Clinical Interviews
Why Cell Therapy Needs a Digital Backbone

August 13, 2026

8 min read

Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional

Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
Drug Discovery Interviews Technology & Manufacturing
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?

August 12, 2026

11 min read

NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients

Building Commercial Readiness in Advanced Therapies
Cell & Gene Interviews Business & Trends
Building Commercial Readiness in Advanced Therapies

August 10, 2026

5 min read

Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: